Compare
Longevity companies, side by side.
Every company profiled on variis, on the same table. Exchange, category, market cap, status, all sourced and dated.
35 of 35 companies. Scroll horizontally on narrow screens.
| Attribute | Alliance Healthcare Group LimitedSGX Catalist | Alterity Therapeutics LimitedASX | AMILI | Atisama Therapeutics (formerly RAGE Biotech / Rage Bio Pty Ltd) | Clarity Pharmaceuticals LtdASX | Clearbridge Health LimitedSGX Catalist | Clinuvel PharmaceuticalsASX | CochlearASX | Cordlife Group LimitedSGX | CSLASX | Dimerix LimitedASX | Eucalyptus Health | Everlab | Genetic Signatures LimitedASX | harrison.ai | Hummingbird Bioscience | IHH Healthcare BerhadSGX | Immutep LimitedASX | MesoblastASX | Micro-X LimitedASX | Mirxes Holding Company LimitedHKEX | Nuevocor Pte Ltd | Nutromics | Orthocell LimitedASX | OUE Healthcare LimitedSGX Catalist | Pro MedicusASX | Raffles Medical Group LtdSGX | Regis Healthcare LimitedASX | ResMedNYSE | Singapore Institute of Advanced Medicine Holdings LtdSGX Catalist | StarpharmaASX | TalkMed Group Limited | Telix PharmaceuticalsASX | Thomson Medical Group LimitedSGX | Vaxxas |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exchange | SGX Catalist | ASX | – | – | ASX | SGX Catalist | ASX | ASX | SGX | ASX | ASX | – | – | ASX | – | – | SGX | ASX | ASX | ASX | HKEX | – | – | ASX | SGX Catalist | ASX | SGX | ASX | NYSE | SGX Catalist | ASX | – | ASX | SGX | – |
| Ticker | SGX Catalist:MIJ | ASX:ATH | – | – | ASX:CU6 | SGX Catalist:1H3 | ASX:CUV | ASX:COH | SGX:P8A | ASX:CSL | ASX:DXB | – | – | ASX:GSS | – | – | SGX:Q0F | ASX:IMM | ASX:MSB / NASDAQ:MESO | ASX:MX1 | HKEX:2629 | – | – | ASX:OCC | SGX Catalist:5WA | ASX:PME | SGX:BSL | ASX:REG | NYSE:RMD / ASX:RMD (CDIs) | SGX Catalist:9G2 | ASX:SPL | – | ASX:TLX / NASDAQ:TLX | SGX:A50 | – |
| Secondary listing | – | NASDAQ | – | – | – | – | – | – | – | – | – | – | – | – | – | – | Bursa Malaysia (primary listing, IHH) | NASDAQ | NASDAQ | – | – | – | – | OTC: ORHHF | – | – | – | – | ASX | – | – | – | NASDAQ | – | – |
| Market cap | Approx. SGD 33 million (market cap SGD 32.69m at a share price of SGD 0.158, quote dated 3 July 2026) | – | – | – | ~A$866m (17 July 2026, stockanalysis.com; share price A$2.32) | Approximately S$6.4m (July 2026, stockanalysis.com; share price S$0.001, 6.44bn shares outstanding) | ~A$360M | ~A$7.4B | – | ~A$53B | ~A$144M (A$0.241 per share, 17 July 2026; down ~57% over the prior twelve months) | – | – | Approximately A$14 million, derived from the 2 July 2026 placement of 23,173,644 shares (10.2 percent) at 6.0 cents, implying about 227 million shares on issue. This is inferred from the transaction terms, not taken from a live exchange quote, so treat it as indicative only. | – | – | – | – | ~A$2.6–2.8B | – | HK$3.66bn (approx US$470m) as at 31 March 2026 per stockanalysis.com, down from a HK$8.29bn debut valuation on 23 May 2025; no verified mid-2026 quote retrieved | – | – | Approximately A$205m to A$236m (July 2026; A$236.03m at the 15 April 2026 close of A$1.06, around A$204.84m at a later close of A$0.76) | – | ~A$21B | Approximately SGD 1.73 billion (17 July 2026, share price SGD 0.94) | About A$1.84 billion (17 July 2026) | ~US$27–28B | approx. SGD 47 million (17 July 2026) | ~A$290M | – | ~US$3.3–3.5B | – | – |
| Category | Diagnostics | ASX listed | Diagnostics | Pharma | Diagnostics | Diagnostics | ASX listed | ASX listed | Regenerative medicine | ASX listed | ASX listed | GLP-1 and metabolic | Diagnostics | Diagnostics | Diagnostics | Pharma | Healthtech | ASX listed | ASX listed | Diagnostics | Diagnostics | Regenerative medicine | Diagnostics | Regenerative medicine | Healthtech | ASX listed | Healthtech | ASX listed | Healthtech | Diagnostics | ASX listed | Healthtech | ASX listed | Healthtech | Healthtech |
| Headquarters | Singapore | Melbourne, Victoria, Australia | Singapore (89 Science Park Drive, #03-09, The Rutherford, Science Park 1) | Melbourne, Victoria, Australia | Eveleigh, Sydney, NSW, Australia | Singapore | Melbourne | Sydney | Singapore | Melbourne | Fitzroy, Melbourne, Victoria, Australia (425 Smith St, Fitzroy 3065) | Sydney, New South Wales, Australia | Melbourne, Victoria, Australia | Newtown, Sydney, NSW, Australia | Sydney, New South Wales, Australia (Level P, 24 Campbell Street, Sydney NSW 2000) | The Galen, 61 Science Park Road, #06-15, Singapore 117525 | Kuala Lumpur, Malaysia | Sydney, New South Wales, Australia | Melbourne | Adelaide, South Australia, Australia | Singapore | Singapore (1 North Buona Vista Link, #10-07 Elementum, Singapore 139691), with offices in Fort Washington, Pennsylvania, USA and Paris, France | Brunswick, Victoria, Australia (420 Victoria Street, Brunswick VIC 3056) | Murdoch, Perth, Western Australia, Australia | Singapore (6 Shenton Way, Singapore 068809) | Melbourne | Singapore | Melbourne, Victoria, Australia | San Diego (founded Sydney) | Singapore | Melbourne | Singapore (101 Thomson Road, #09-02 United Square, Singapore 307591) | Melbourne | Singapore | Brisbane, Queensland, Australia |
| Status | Active | Active | Private | Private | Active | Active | Active | Active | Active | Active | Active | Acquired | Private | Active | Private | Private | Active | Active | Active | Active | Active | Private | Private | Active | Active | Active | Active | Active | Active | Active | Active | Delisted | Active | Active | Private |
| Longevity exposure | Qualifies on both limbs: listed on SGX Catalist under MIJ and headquartered in Singapore (25 Bukit Batok Crescent). Alliance is an investment holding company running an integrated Singapore healthcare network: GP clinic services (My Family Clinic), specialist care, managed healthcare solutions sold to corporates and insurers, pharmaceutical services, radiology, home care (JagaMe) and a digital health app (HeyAlly). It states access to more than 2,000 in-house and partner medical facilities in Singapore, and had 395 employees with a July-June fiscal year. The longevity-relevant activity is preventive and occupational health screening delivered at scale through corporate health plans and the GP network, plus imaging and teleconsultation that route screening findings into follow-up care. It is a care-delivery and screening distribution business, not a developer of ageing-biology therapeutics or biomarker tests, so exposure is to the preventive-screening and primary-care layer rather than to any geroscience intervention. | Clinical-stage biotech developing disease-modifying drugs for neurodegenerative disease. Lead candidate ATH434 is an oral small molecule designed to reduce excess iron accumulation in the brain and inhibit aggregation of alpha-synuclein, the protein implicated in Multiple System Atrophy and related synucleinopathies. It targets the underlying biology of age-related neurodegeneration rather than symptoms, which is the longevity-relevant part. ATH434 has completed a randomised placebo-controlled Phase 2 trial in MSA plus an open-label Phase 2 in advanced MSA, and the company is working toward a pivotal Phase 3. It is a single-asset, pre-revenue developer, so exposure is binary on that program. | Microbiome science company running a multi-ethnic Asian gut microbiome biobank and reference database, which it uses to interpret consumer and clinician-ordered stool tests. Commercial output is diagnostic rather than therapeutic: a gut microbiome test kit and an enhanced version, four targeted probiotic formulations (immune-metabolic, complete, cognitive, digestive), microbiome restoration therapy, and AMILI Optimise Plus, a metabolic health programme that pairs microbiome profiling with continuous glucose monitoring and nutritionist input. Distribution runs through a partner clinic network. Longevity relevance is indirect: it sits in the metabolic-health and personalised-nutrition layer, measuring and modifying a biomarker set (gut composition, glycaemic response) associated with cardiometabolic risk, not intervening in ageing biology directly. Efficacy claims for microbiome-guided nutrition remain contested in the literature; the company's own database size claims are self-reported and not independently verified here. | Develops inhaled splice-switching oligonucleotide (RNA) drugs aimed at the RAGE receptor, the receptor for advanced glycation end-products. Lead candidate RB042 inhibits full-length RAGE while increasing the soluble decoy form esRAGE in the lung, with the goal of damping chronic airway inflammation. It is in a Phase 1 trial (NCT07285122) in healthy volunteers and healthy smokers, targeting COPD; the stated pipeline also covers alpha-1 antitrypsin deficiency, neutrophilic asthma and idiopathic pulmonary fibrosis. The longevity relevance is mechanistic rather than claimed by the company: RAGE-AGE signalling sits at the intersection of two recognised ageing hallmarks, chronic sterile inflammation and the accumulation of glycation end-products, and the company itself positions RB042 as a respiratory disease drug, not an ageing intervention. Note the company was spun out as RAGE Biotech, jointly founded with IP Group Australia, Monash University, Murdoch University, the University of Western Australia, and the Baker and Perron institutes, and now operates as Atisama Therapeutics. | Clinical-stage radiopharmaceutical company. Its SAR Technology platform pairs copper-64 (imaging) and copper-67 (therapy) with the same targeting molecule, so a single agent can both find and treat a tumour. Three candidates: SAR-bisPSMA (prostate cancer, lead), SAR-Bombesin (prostate and other PSMA-negative tumours) and SARTATE (neuroendocrine tumours). Relevance to the variis universe is late-life cancer detection and treatment: prostate and neuroendocrine cancers are strongly age-associated, and the company's clinical case rests on detecting recurrent disease at low PSA levels, i.e. earlier than standard-of-care imaging. Nothing in the pipeline targets ageing biology directly. Qualifies on limbs (a) and (b): ASX-listed and Australian-headquartered. Note it is pre-revenue and pre-approval; no product has regulatory approval. | Operates medical clinics and diagnostic services across Singapore, the Philippines and Hong Kong, including imaging, general health screening and vaccination. Its longevity relevance is limited and indirect: it is a clinic and screening operator, not a company developing ageing-biology interventions or aging-specific biomarker panels. The relevant exposure is preventive health screening infrastructure in Southeast Asia, which sits adjacent to the longevity clinic market. Financial condition is weak: FY2025 revenue of S$9.93m was flat year on year while net loss widened to S$12.91m, and the shares trade at S$0.001 on the SGX Catalist board with a market capitalisation of roughly S$6.4m. Include only with that caveat. | Melanocortin photomedicine (tissue resilience). | Hearing implants (hearing loss is a modifiable dementia-risk factor). | Cordlife collects, processes and cryogenically stores umbilical cord blood and cord tissue for private clients across several Asian markets, operating storage facilities rather than developing therapies. Its longevity relevance is as infrastructure for cell-based and regenerative medicine: banked haematopoietic stem cells are held against future transplant or therapeutic use. It is a storage and services business, not a therapeutics developer, and it does not run clinical programmes in ageing biology. Inclusion is on the listing limb (SGX Mainboard) and the Singapore headquarters, both confirmed. Fundamentals should be treated as unconfirmed: the company is under active Singapore Ministry of Health regulatory restriction and its FY2025 accounts carry a disclaimer of opinion. | Plasma immunoglobulins, gene therapy. | Clinical-stage biopharmaceutical company. Its lead candidate DMX-200 (repagermanium, a chemokine receptor CCR2 antagonist given on top of an angiotensin II receptor blocker) is in the Phase 3 ACTION3 trial for focal segmental glomerulosclerosis (FSGS), a rare glomerular disease that causes scarring of the kidney's filtering units and progressive loss of kidney function toward end-stage renal disease. The trial's primary endpoint is reduction in proteinuria, with eGFR decline as a longer-term measure. A second program, DMX-700, targets orphan respiratory and renal indications and is at an earlier stage. The longevity relevance is narrow and indirect: this is rare-disease nephrology, not a geroscience or ageing-biology program. It is relevant to healthspan only insofar as declining kidney filtration is one of the core organ-decline endpoints, and DMX-200 addresses a specific genetic and idiopathic kidney disease rather than age-related renal decline in the general population. No approved products and no revenue from product sales; the company is pre-approval and dependent on trial outcomes and regional licensing partners. | Telehealth group founded in Sydney in 2019, operating four direct-to-consumer clinical brands: Juniper (weight management built around GLP-1 receptor agonist prescribing plus coaching), Pilot (men's health, including weight, hair loss and sexual health), Software (dermatology and skincare) and Kin (contraception, fertility and pregnancy). Its longevity relevance is distribution rather than discovery: it does not develop drugs or run biology research, but is one of the larger channels in Australia through which GLP-1 metabolic therapy is prescribed, titrated and monitored remotely, with adherence support attached. Reported 2024 revenue of A$120.9m and an after-tax loss of A$15.2m. Qualifies under limb (b), Australia-headquartered, though since June 2026 it has been a wholly owned subsidiary of NYSE-listed Hims & Hers Health rather than an independent company. | Runs a preventive health screening and diagnostics service for individual paying members. A single intake bundles whole-body MRI, CT coronary angiography, DEXA body composition and bone density, VO2 max and isometric strength testing, ECG, continuous glucose monitoring and blood panels covering more than 100 biomarkers across cardiovascular, metabolic, hormonal, inflammatory, toxicological and performance domains. Results are pulled into one record alongside clinician review, specialist referral, prescriptions and wearable data, with the stated aim of catching disease risk earlier than standard primary care. Pricing is tiered, from A$499 for a blood biomarker package to A$2,999 a year for the full programme. The longevity relevance is screening and early detection, not any therapeutic or ageing-modifying intervention: the company sells testing and care coordination, and no published outcome data establishing that its screening extends life or reduces mortality was found in the sources reviewed. | Molecular diagnostics company built on its proprietary 3base sample-chemistry platform, which converts non-methylated cytosines before amplification to reduce sequence complexity and allow highly multiplexed real-time PCR. It sells EasyScreen kits and the GS1 automated workflow to clinical laboratories for gastrointestinal (bacterial, viral, parasitic), respiratory, and vaccine-preventable pathogen detection, with customers in Australia, the UK, and the US. Longevity relevance is peripheral and indirect: the exposure is infectious disease testing infrastructure, not ageing biology, biological age measurement, or any geroscience intervention. It belongs in the universe on the diagnostics limb and on ASX listing, not on scientific proximity to healthspan. Nothing in its product line targets ageing mechanisms. | Builds clinical AI software that reads medical images and flags findings for clinicians. Its radiology products cover chest X-ray and non-contrast head CT (the company and press reporting cite up to 124 findings on chest X-ray and up to 130 on non-contrast head CT), with a separate pathology line aimed at slide review and workflow. The longevity relevance is earlier detection of disease at scale rather than any intervention on ageing biology: the software is deployed in over 1,000 healthcare facilities and is sold into radiology and pathology providers, including shareholder-linked networks Sonic Healthcare and I-MED Radiology. It does not develop drugs or therapeutics. | A Singapore-headquartered antibody drug developer. It designs monoclonal antibodies and antibody-drug conjugates against targets it selects computationally, then develops them for cancer and autoimmune disease. Current clinical assets are HMBD-001 (anti-HER3 antibody) and HMBD-501 (a HER3-directed antibody-drug conjugate, dosed in its first Phase I patient in January 2026). It has also out-licensed programmes: HMBD-002 (anti-VISTA) to Percheron Therapeutics in June 2025, and an undisclosed-target antibody to Immunome in January 2025. Its longevity relevance is indirect rather than direct. It does not work on ageing biology, senescence, metabolic ageing or healthspan endpoints. The connection is that cancer is a leading age-related cause of death, so better-targeted oncology therapeutics extend life in an older population. Read as an oncology biotech that sits in the SG/AU universe on headquarters grounds, not as a geroscience company. | Operates a private hospital network of 89 hospitals across 10 countries (Malaysia, Singapore, Turkiye, India, China, Hong Kong, Brunei, Bulgaria, North Macedonia, Netherlands, Serbia), including the Mount Elizabeth, Gleneagles and Parkway brands in Singapore. Its longevity relevance is delivery-side rather than therapeutic: it is the largest listed vehicle for age-related clinical care in Asia, with revenue concentrated in cardiology, oncology and orthopaedics, the specialties that scale with an ageing population. It also runs an SGD 80 million innovation fund backing startups in cancer diagnostics, digital health, proton therapy, mental health and sleep disorders. It does not develop geroprotective drugs or biological-age interventions. Inclusion is confirmed under limb (a): SGX secondary line Q0F verified on a live SGX healthcare sector listing. | Immutep develops immunotherapies built around LAG-3, an immune checkpoint protein that regulates T-cell activity. Its portfolio runs in two directions from the same biology: agonist-style candidates (led by eftilagimod alfa, a soluble LAG-3 protein) intended to stimulate antigen-presenting cells and T-cells against tumours, and antagonist candidates intended to damp down T-cell activity in autoimmune disease. That two-sided position on T-cell regulation is what makes it relevant to the immune-ageing (immunosenescence) axis rather than to a single tumour type. It is not a geroscience company and does not run ageing-endpoint trials; the longevity link is mechanistic, via immune regulation, not by stated intent. Inclusion is on both limbs of the rule: ASX-listed and Sydney-headquartered. The honest negative: its most advanced oncology programme failed a Phase III interim futility analysis in March 2026, so the near-term clinical case rests on the remaining earlier-stage assets. | First FDA-approved MSC product (Ryoncil). | Micro-X designs and manufactures X-ray and CT imaging hardware built on carbon-nanotube ("cold cathode") emitters, which let the tube be far smaller and lighter than conventional thermionic X-ray tubes. Its commercial product is the Rover / Rover Plus mobile digital radiography unit, a portable X-ray system used where patients cannot easily be moved to a fixed radiology suite: emergency departments, intensive care, operating theatres, remote and field settings. In development is an ultra-lightweight head CT scanner intended to be carried in an ambulance so that stroke can be imaged and triaged before the patient reaches hospital, plus earlier-stage portable full-body CT and lung CT work. The longevity relevance is infrastructural rather than therapeutic: it addresses point-of-care imaging for immobile and frail patients and time-to-diagnosis in stroke, a condition whose incidence rises sharply with age. It is not a geroscience or ageing-biology company, and the Micro-X site does not itself market Rover as an aged-care product, so the aged-care framing should be treated as an inference about the use case rather than a company claim. Micro-X also sells non-medical security screening products (baggage and checkpoint scanners), so medical imaging is only part of the revenue base. | Develops and sells blood-based microRNA diagnostic tests for early cancer detection. Its lead product, GASTROClear, is a 12-biomarker blood panel for gastric cancer screening; it also markets LUNGClear for lung cancer and Fortitude infectious-disease assays. The longevity relevance is early detection rather than any ageing-biology intervention: catching cancer at a screenable, asymptomatic stage in high-risk adults. Qualifies for the variis universe on the headquarters limb (Singapore), not the exchange limb, as it is listed on HKEX rather than SGX or ASX. | Clinical-stage genetic medicines company developing gene therapies for inherited cardiomyopathies, using a mechanobiology approach that targets the mechanical stress signalling inside failing heart muscle cells rather than correcting the mutated gene directly. Lead asset NVC-001 is an AAV-delivered therapy for LMNA-related dilated cardiomyopathy, an aggressive genetic heart-muscle disease with no targeted treatment. Longevity relevance is disease-specific rather than general: it aims to halt progression of a condition that causes heart failure and early death in carriers, not to modify ageing biology broadly. Both Singapore HQ and incorporation as a Pte Ltd confirmed on the company site, so it meets limb (b) of the inclusion rule. | Nutromics builds a wearable "lab-on-a-patch" that uses DNA-aptamer biosensors on a microneedle array to measure molecules in interstitial fluid continuously, rather than at single points via blood draws. The lead indication is therapeutic drug monitoring of vancomycin in intensive care sepsis patients, an antibiotic with a narrow therapeutic window that is hard to dose correctly. The company has also shown simultaneous real-time measurement of two antibiotics (vancomycin and tobramycin) on one device in animal models, and is working on a sepsis management patch. The longevity relevance is infrastructural rather than an intervention: it is a platform for continuous biomarker tracking that could extend beyond drugs to other dynamic analytes, shifting diagnostics from episodic lab tests to trend data. No product has regulatory approval anywhere; the company states FDA clearance for vancomycin monitoring is targeted from 2028, so nothing is in clinical use today. | Orthocell makes collagen-based implantable devices and autologous cell therapies for repairing tissue that degrades or fails to heal with age: peripheral nerve, tendon, bone and cartilage. Three commercial products: Remplir, a collagen wrap used in peripheral nerve repair surgery; Striate+, a collagen membrane for dental bone regeneration; and OrthoACI, an autologous chondrocyte implantation therapy for cartilage defects. Remplir is the commercial driver, cleared for sale in 45 US states with distribution also in Canada and Australia. The longevity relevance is demand-side rather than mechanistic: this is surgical tissue repair for an older population, not an intervention targeting biological ageing itself. Revenue is real but small (A$13.2m in FY2026), and US unit volumes remain modest (119 devices in the June 2026 quarter). | Qualifies on both limbs: listed on SGX Catalist under 5WA and headquartered in Singapore. It is an investment holding company that owns, operates and invests in healthcare businesses across Singapore, China, Myanmar, Indonesia and Japan, running hospitals and specialist clinics, supplying medical equipment and pharmaceuticals, and holding healthcare property and development assets. Parent is OUE Limited. Its longevity relevance is indirect and infrastructural rather than biological: it is a private healthcare services operator, not a developer of ageing-targeted therapeutics or diagnostics. The nearest direct link is its stated push into specialised care and an integrative medicine offering combining traditional and Western treatment, which sits adjacent to preventive and wellness-oriented care. There is no disclosed geroscience, senolytic, biological-age testing or longevity-clinic programme. Treat it as a delivery-channel holding in the SG universe, not an intervention developer. Financial scale was not verified: the shares traded around SGD 0.03 on 17 July 2026 per StockAnalysis, but no market capitalisation figure was retrieved, so that field is left null rather than estimated. | Imaging/radiology AI (early detection). | An integrated private healthcare provider, not a longevity biotech. Founded 1976 and headquartered at Raffles Hospital, 585 North Bridge Road, Singapore, it runs family medicine clinics, specialist centres, hospitals, dental and Chinese medicine practices, insurance and healthcare products across Singapore, China, Vietnam, Cambodia and Japan. The longevity-relevant part is a preventive and chronic-care line rather than the group as a whole: health screening packages, an executive medical centre, statutory health checks, corporate health programmes covering more than 7,000 corporate clients, and chronic disease management delivered through its primary care network. That makes it the closest SGX-listed proxy for a clinical healthspan business, but the revenue base is conventional hospital and clinic services, and the company makes no ageing-biology or lifespan-extension claim. Treat it as delivery infrastructure for preventive medicine, not as an intervention developer. | Operates aged care and later-life accommodation services across Australia: residential aged care homes, home care packages delivered in people's own homes, short-term and respite care, and retirement living. Facilities span Queensland, Victoria, New South Wales, Western Australia, South Australia, Tasmania and the Northern Territory. Its relevance to longevity is economic and infrastructural rather than biomedical: it does not develop drugs, diagnostics or interventions that alter ageing biology. It is a listed proxy for how Australia funds and delivers care in the final decades of life, with revenue tied directly to the Commonwealth's AN-ACC funding model (about A$295 per resident per day) and to resident co-contributions. Inclusion rule is met on both limbs: ASX-listed and Australian headquartered. | Sleep/respiratory; GLP-1 screening beneficiary. | Operates a single-site Singapore medical centre built around advanced imaging and radiation oncology. Two reported segments: medical diagnostics and treatments (cancer diagnostics, nuclear medicine, general health screening, aesthetic services) and radiation therapy and medical oncology (proton beam therapy, photon radiation therapy, medical oncology). Its stated clinical focus spans cancer, neurodegenerative and cardiovascular disease detection. The longevity-relevant part is the diagnostics and imaging arm: high-resolution and nuclear-medicine imaging plus paid health screening is early-detection infrastructure, the same category as preventive screening plays. The proton-beam oncology business is treatment for existing disease, not a longevity intervention, and is the larger capital commitment. There is no geroscience, biomarker-of-ageing, or therapeutic-development activity here. It is a small, loss-making clinical operator: FY2025 revenue SGD 15.71m, down 5.6% year on year, with a net loss of SGD 27.05m, and a market capitalisation under SGD 50m. Note the corporate site www.sam.com.sg did not resolve on repeated attempts, so the business description above rests on exchange-data aggregators rather than company disclosure. | Dendrimer drug-delivery. | Runs private medical oncology and palliative care practices in Singapore, delivered mainly through Parkway Cancer Centre, with sub-specialty coverage of breast, head and neck, gastro-intestinal, uro-gynaecological and haematological cancers, plus ancillary health services, medical technology services and some overseas operations. The longevity relevance is indirect and delivery-side rather than mechanistic: it is late-stage disease treatment and supportive care, not an ageing-biology intervention. Inclusion rule is met on both limbs (Singapore-headquartered, and formerly SGX Mainboard listed). It is no longer investable on public markets: the shares were delisted with effect from 15 September 2025 after a scheme-of-arrangement privatisation by TW Troy Limited. The former SGX counter code was 5G3; the ticker field is left null because that security no longer trades. The claim that the acquiring vehicle sits under pan-Asian oncology group Tamarind Health was not confirmed by the sources retrieved here, so it is not asserted. | Radiopharmaceutical theranostics (cancers of ageing). | Operator of private hospitals and clinics, with the group's distinctive concentration in women's health, fertility and maternity care. Its Singapore assets include Thomson Medical Centre and a network of women's clinics, fertility/IVF services and paediatric centres; it also operates in Malaysia (Thomson Hospital Kota Damansara) and Vietnam (FV Hospital, acquired 2023). The longevity-relevant limb is reproductive ageing: IVF and fertility treatment address declining ovarian reserve and age-related fertility loss in an ageing, low-birth-rate region. This is clinical service delivery, not geroscience research; the group does not develop ageing-directed therapeutics or biomarkers. Inclusion is on listing and HQ grounds (SGX-listed, Singapore-headquartered), with fertility as the thematic tie rather than any lifespan or healthspan intervention. | Vaxxas is a private Brisbane biotechnology company developing a high-density microarray patch (HD-MAP), a needle-free vaccine delivery device derived from University of Queensland research. The patch carries thousands of vaccine-coated microprojections that are pressed into the skin for a few seconds, depositing vaccine into the immune-cell-rich layer immediately below the surface rather than into muscle. The claimed advantages are dose-sparing, reduced cold-chain dependence, and the possibility of self-administration at home. It meets the inclusion rule on limb (b), Australian headquarters, and the company confirms it is private (Vaxxas Pty Ltd, Series D equity plus debt, August 2025). The longevity link is indirect and should be read that way: Vaxxas is a delivery platform, not a therapeutic, and makes no ageing-biology claim. The relevance to a longevity universe is preventive-health and immunosenescence adjacency, since intradermal delivery is the route most often studied for improving vaccine response in older adults whose immune systems respond poorly to intramuscular injection, and since a lower-cost, cold-chain-light delivery format bears on population-scale preventive coverage. Vaxxas has not published a specific older-adult immunogenicity programme that was verifiable from the sources opened here. Treat it as peripheral to the core longevity thesis. |
| Recent inflection | FY2025 (year ended 30 June 2025): revenue rose 13.43% to SGD 77.12 million and net earnings rose 111.74% to SGD 1.52 million, per StockAnalysis financial summary; the shares subsequently traded up around 32% over the trailing year to July 2026 from an all-time low of SGD 0.088 on 7 January 2026. | 19 May 2026: Alterity presented Phase 2 ATH434 data at three meetings (ISMRM, MDSANZ, MSA Symposium at UCL), reporting a significant effect at 50 mg twice daily on functional decline (-4.0 points, p=0.035, roughly 48% slowing) and reduced swallowing decline (p=0.003 at 50 mg). The company also reported two positive Type C interactions with the US FDA and said it was on track for an End-of-Phase 2 FDA meeting around mid-2026 to enable a pivotal Phase 3. | On 21 April 2026, Calbee launched its Body Granola personalised nutrition service in Singapore with AMILI supplying the gut microbiome testing component, extending AMILI from direct-to-consumer testing into a consumer packaged goods partnership (NutraIngredients, 22 April 2026). | 15 May 2026: now operating as Atisama Therapeutics, the company announced RB042 had advanced into multiple ascending dose cohorts of its Phase 1 trial after completing three of four single ascending dose cohorts, with readouts expected in H2 2026, and appointed Bernard Coulie as Chair of the Board (source: Atisama press release carried by FNArena, 16 May 2026). This followed the A$29m Series A announced 13 November 2025, led by IP Group Australia and Hostplus with Monash Ventures. | 14 October 2025: Clarity announced the investigator-initiated Phase II Co-PSMA trial met its primary endpoint, with 64Cu-SAR-bisPSMA PET/CT detecting significantly more lesions per patient than standard-of-care 68Ga-PSMA-11 PET/CT in 50 post-prostatectomy patients with low PSA (company announcement, claritypharmaceuticals.com). This was followed on 14 April 2026 by a commercial manufacturing agreement with Nucleus RadioPharma for 64Cu-SAR-bisPSMA. | FY2025 results (year ended 31 December 2025, adopted at the AGM on 23 April 2026) showed revenue of S$9.93m, essentially flat year on year, with net loss widening to S$12.91m, roughly 258% worse than 2024. The company has since continued issuing shares at sub-cent prices, including an allotment of 2.1m shares at S$0.0018 in June 2026. | CUV105 Ph3 vitiligo enrolled; results H2 2026. | Brutal 2026, fell up to ~62%; record −41% single session (Apr). | On 23 April 2026, ahead of its 27 April 2026 AGM, Cordlife disclosed that its independent auditors had issued a disclaimer of opinion on the financial statements for the year ended 31 December 2025, citing unresolved regulatory and legal matters and an inability to verify opening balances as at 1 January 2025. This followed the Ministry of Health's one-year suspension of its licence to collect, test, process or store new cord blood units, effective 26 November 2025, and an MOH directive to replace the Chief Governance Officer and review laboratory records for roughly 160 cord blood units collected since January 2025. Source: Minichart AGM report, 23 April 2026. | Decade-low price; ~US$5B Vifor impairment; demerging Seqirus (flu vaccines) by end FY26. | 28 April 2026: Dimerix announced completion of an external blinded assessment of ACTION3's statistical assumptions, confirming the study remains powered at greater than 90% to detect a treatment effect on the proteinuria primary endpoint. In the same announcement the company and its commercial partners decided NOT to proceed with the interim analysis that would have supported a US Accelerated Approval filing, citing added cost, extended timelines, the need for additional confirmatory endpoints, and a reduced probability of success on final endpoints. The stated rationale was a changed FSGS regulatory landscape, including FDA confirmation that proteinuria is acceptable for traditional (full) approval and a recent FDA approval of another FSGS therapy on proteinuria. Net effect: a cleaner path to traditional approval, but the loss of a nearer-term accelerated-approval catalyst, consistent with the shares trading around 57% below their level a year earlier. | Hims & Hers Health (NYSE: HIMS) completed its acquisition of Eucalyptus on 2 June 2026, for aggregate consideration of up to US$1.15bn subject to adjustments, per the acquirer's press release filed as an 8-K exhibit with the SEC. The deal was announced in February 2026; founder Tim Doyle moved into an international operations role at the acquirer. | Raised a A$65m Series A led by Airtree Ventures, announced 17 June 2026, with Plural, Left Lane Capital, b2venture and cricketer Pat Cummins participating. It came less than twelve months after a US$10m (A$15m) seed led by Left Lane Capital reported 24 July 2025, when the company cited a waitlist in the tens of thousands and planned international expansion (SmartCompany, 17 June 2026; Longevity.Technology, 24 July 2025). | On 2 July 2026, BCAL Diagnostics acquired a 10.2 percent stake (23,173,644 shares at 6.0 cents, A$1,390,119) in Genetic Signatures, framed as a strategic position in a complementary diagnostics company with existing PCR manufacturing, regulatory clearances, and distribution in Australia, the UK, and the US. The stake was taken against a weak backdrop: H1 FY26 revenue of about A$8.7 million (up 2.4 percent year on year) with the board conceding that US sales of its key commercialised product had fallen short of expectations, and the shares near 52-week lows. Source: Sharecafe, 2 July 2026, corroborated by Kalkine and an Investing.com H1 FY26 earnings call transcript. | On 29 January 2025 the Australian government's National Reconstruction Fund Corporation took a A$32m equity stake as part of harrison.ai's Series C, reported by ACS Information Age the same day; the company states more than US$240m raised to date. | 6 January 2026: first patient dosed in the Phase I clinical trial of HMBD-501 in patients with advanced HER3-expressing solid malignancies (company news page, hummingbirdbioscience.com/news). | 13 July 2026: IHH set out a scaled-up India programme via its Fortis Healthcare subsidiary, targeting 10,000 beds by 2030 (roughly 8,000 visible through brownfield expansion), naming India as a global business services hub, and directing its SGD 80 million innovation fund toward AI, precision medicine and advanced oncology technology. Reported by Business Today. | 13 March 2026: the Independent Data Monitoring Committee recommended discontinuing the Phase III TACTI-004 trial of eftilagimod alfa in first-line non-small cell lung cancer following a planned interim futility analysis. Enrolment was halted and the study wound down. The company said its cash runway would extend well beyond the previously guided Q2 CY2027, without giving a revised figure at the time. Immutep's Nasdaq ADRs fell from US$2.76 to US$0.48 on the announcement, about 83 percent. Source: GlobeNewswire company release, 13 March 2026. | Apr 2026 FDA IND clearance for Ryoncil in Duchenne MD; Ryoncil Y1 revenue ~US$100M. | On 24 September 2025 Micro-X announced it had been awarded a $4.4 million grant to fund a world-first trial of a stroke-capable ambulance integrating its ultra-lightweight head CT scanner into frontline emergency services. As of the company's 9 July 2026 investor newsletter, the head CT programme had progressed to human imaging trials, alongside portable full-body CT development under the ARPA-H PARADIGM contract (announced 13 February 2025, up to US$16.4m / A$25m). Source: Micro-X news page, micro-x.com/news/. | 9 October 2025: China's NMPA granted GASTROClear Class III IVD registration, making it the first non-invasive blood test approved for gastric cancer screening in China, cleared for high-risk adults aged 45 to 74 on the basis of a 9,472-subject prospective trial across seven Chinese academic centres (Mirxes media release). | On 10 June 2025 the company announced FDA clearance of its IND for NVC-001 in LMNA-related dilated cardiomyopathy, clearing the way for first-in-human clinical work. This followed the close of a US$45m Series B on 6 May 2025 raised to fund that clinical development, per the company's own newsroom (https://www.nuevocor.com/news). | April 2026: Nutromics was awarded about A$3m within a A$11.2m Cooperative Research Centres Projects consortium to develop a sepsis management patch, and appointed Tom Prescott as Board Chair ahead of a planned 2027 commercial launch (company media page, nutromics.com/media). Earlier, in October 2025 it presented what it described as the first real-time in vivo multiplexed data measuring vancomycin and tobramycin simultaneously on one device at IATDMCT. | 12 July 2026: Orthocell reported record FY2026 revenue of A$13.2m, up 44% year on year, with a record June quarter of A$3.8m. US Remplir distribution now reaches roughly 50% of the US population, hospital purchasing accounts rose 27% to 70, surgeon adoption rose 55% to 76, and the company secured approval across US Department of Defence and Veterans Affairs networks, opening access to 221 military and veterans medical centres. Source: Proactive Investors, 12 July 2026. | At its annual general meeting on 24 April 2026 (minutes lodged with SGX on 22 May 2026), management reiterated a three-part strategy of an asset-light model, strategic partnerships and regional Asian expansion, and flagged a shift toward specialised care including a planned integrative medicine service combining traditional and Western treatment. Source: SGX-hosted AGM minutes, https://links.sgx.com/FileOpen/OUEH%20-%20Minutes%20of%20AGM%20held%20on%2024%20April%202026.ashx?App=Announcement&FileID=889933 | Down ~40% off high on AI-disruption fears. | FY2025 (year ended 31 December 2025) results released 22 February 2026: revenue of SGD 765.6 million, up 1.8% on FY2024's SGD 752.4 million, with net income of SGD 70.6 million, up 13.4% on SGD 62.2 million, so margin expansion rather than top-line growth drove the year. The stock nonetheless traded near its 52-week low of SGD 0.90 in July 2026. Source: stockanalysis.com SGX:BSL financials and quote pages, and the SGinvestors announcement calendar showing the 22 February 2026 full-year results release. | The new Aged Care Act commenced 1 November 2025, replacing the 1997 legislation and resetting provider funding and resident co-contribution rules. Regis reported H1 FY26 revenue of about A$668 million on 23 February 2026, up 18% year on year, with operating cash flow of A$291.7 million (up 40%), capital expenditure of A$102.1 million (more than tripled), staff costs up 22%, and an interim dividend of A$0.09 per share fully franked. Source: Australian Stock Report, "Regis Healthcare (ASX:REG) Posts 18% Revenue Surge". | Acquired Noctrix Health (Jun 2026). | FY2025 results (financial year ended 31 December 2025) showed revenue of SGD 15.71m, down 5.63% year on year, with a net loss of SGD 27.05m, narrower than FY2024. The shares traded at SGD 0.027 on 17 July 2026, down 6.9% year to date, with the next earnings report scheduled for 29 August 2026 (stockanalysis.com, retrieved 19 July 2026). | Micro-cap; DEP assets in Ph2. | Privatised by scheme of arrangement: shareholders approved the scheme on 15 July 2025, the Singapore court sanctioned it on 18 August 2025, SGX RegCo granted in-principle delisting approval on 21 August 2025, trading was suspended from 9.00 a.m. on 22 August 2025, and the shares were delisted from the SGX Mainboard with effect from 15 September 2025, with the acquirer named in the company announcement as TW Troy Limited (source: TalkMed SGX announcement dated 21 August 2025; delisting date confirmed by sginvestors.io). | +35% YoY; scaling three segments. | Board and financial reset in early 2026: Tong Kooi Ong was appointed Independent Non-Executive Chairman effective 1 February 2026, succeeding Ng Ser Miang, in a move linked to the group's capital-intensive Johor Bay development in the Johor-Singapore Special Economic Zone. H1 2026 revenue rose to S$215.9m from S$201.9m a year earlier, with the net loss narrowing to S$10.2m, following an FY2025 loss driven by interest expense on the FV Hospital (Vietnam) acquisition and weaker Malaysian performance. (Reported via Simply Wall St; not independently confirmed against the SGX filing.) | On 25 August 2025 Vaxxas announced approximately A$90 million in new financing, comprising A$49.22 million of Series D equity and A$40 million in debt facilities, led by SPRIM Global Investments with participation from new investor LGT Crestone and existing investors OneVentures and Brandon Capital-Hostplus. The company said the round funds semi-automated manufacturing lines and later-stage clinical trials and provides runway into the second half of 2027, and that founding CEO David Hoey would move to a strategic advisor role. Source: GlobeNewswire release, 25 August 2025. Subsequent company-disclosed milestones on vaxxas.com/news include a TGA manufacturing licence (15 December 2025), the appointment of David Peacock, formerly of Merck's global vaccines division, as CEO (8 January 2026), and participation in a consortium awarded an EU tender for next-generation influenza vaccines (26 February 2026). |
Not investment advice.